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H5N1 avian influenza viruses are continuing to spread in waterfowl in Eurasia and to threaten the health of avian and mammalian species. The
possibility that highly pathogenic (HP) H5N1 avian influenza is now endemic in both domestic and migratory birds in Eurasia makes it unlikely
that culling alone will control H5N1 influenza. Because ducks are not uniformly killed by HP H5N1 viruses, they are considered a major
contributor to virus spread. Here, we describe a reverse genetics-derived high-growth H5N3 strain containing the modified H5 of A/chicken/
Vietnam/C58/04, the N3 of A/duck/Germany/1215/73, and the internal genes of A/PR/8/34. One or two doses of inactivated oil emulsion vaccine
containing 0.015 to 1.2 μg of HA protein provide highly efficacious protection against lethal H5N1 challenge in ducks; only the two dose regimen
has so far been tested in chickens with high protective efficacy.
© 2006 Elsevier Inc. All rights reserved.Keywords: H5N1; Influenza; Oil-emulsion; Vaccines; Efficacy; Ducks; ChickensIntroduction
The H5N1 avian influenza virus that emerged in 1996 in
southern China (Xu et al., 1999) is now endemic in domestic
poultry in the region and has continued to spread across Asia
(Horimoto and Kawaoka, 2005; Lipatov et al., 2004).
Descendants of this virus continue to ravage the poultry
industries of Asia. The virus has infected 121 humans in
Vietnam, Thailand, Cambodia, and Indonesia, killing 62. In the
summer of 2005, this H5N1 virus caused a lethal outbreak of
influenza in wild birds (mainly bar-headed geese) in Qinghai
Lake in western China (Chen et al., 2005; Liu et al., 2005) and
subsequently spread to poultry in Russia, Kazakhstan, Mon-
golia, and Turkey. The available evidence shows that the Z⁎ Corresponding author. Rose Marie Thomas Chair, Division of Virology,
Department of Infectious Diseases, St. Jude Children's Research Hospital,
World Health Organization Collaborating Center for Studies on the Ecology of
Influenza in Animals and Birds.
E-mail address: robert.webster@stjude.org (R.G. Webster).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.01.044genotype of highly pathogenic H5N1 influenza virus is now
endemic in wild migratory birds and will continue to spread
across Europe.
Although quarantine, restricted movement, and culling of
infected and adjacent flocks is the traditional method of
controlling and eradicating highly pathogenic avian influenza
viruses (Lee et al., 2005), other strategies, including
improved biosecurity and vaccination, have been adopted
in some countries. Hong Kong SAR, China successfully
controlled H5N1 in 2004, although poultry in the surround-
ing countries were ravaged by highly pathogenic H5N1
avian influenza (Sims et al., 2003; Ellis et al., 2004). The
changes adopted in Hong Kong were: (1) a ban on ducks
and geese (the primary source of influenza) and quail
(potential amplifiers) in the live poultry markets; (2) im-
proved sanitation of live markets with two clean days per
month; (3) vaccination of all chickens and serologic
monitoring of sentinel unvaccinated chickens in each poultry
shed to ensure absence of virus shedding. No H5N1 virus
has been detected in domestic poultry or people in Hong
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successfully control the spread and interspecies transmission
of H5N1 virus.
Vaccination of chickens and turkeys with inactivated, oil
emulsion influenza vaccines is known to prevent influenza
disease signs and reduce virus spread and shedding (Karuna-
karan et al., 1987; Stone, 1987; Brugh et al., 1979). A second
strategy for vaccinating chickens is infection with recombinant
fowlpox virus containing an influenza virus HA gene Swayne et
al., 1997, 2000; Qiao et al., 2003). However, the available
vaccines do not induce sterilizing immunity in chickens for a
number of potential reasons, including lack of antigenic match
between the vaccine and circulating strain and insufficient viral
antigen in the vaccine. Agricultural influenza vaccines, unlike
their human counterparts, are not standardized for antigen
content and are delivered in adjuvants composed of water in oil
emulsions (Stone, 1987). Such vaccines must be inexpensive
because the profit margin in raising poultry is small. Reverse
genetics was used to create an H5N3 vaccine for poultry (Liu et
al., 2003) and appears to offer a means of preparing
inexpensive, efficacious vaccines to highly pathogenic H5N1
influenza viruses. The N3 neuraminidase was used to allow
distinction between infected and vaccinated animals (the DIVA
strategy) (Capua et al., 2003). A dose of HA protein as small as
1.2 micrograms protected chickens from lethal H5N1 challenge
and markedly reduced virus shedding by infected birds.
Nevertheless, a small number of birds shed small amounts
(depending on the vaccine dose) of H5N1 influenza virus (Liu
et al., 2003).
There is limited information about the immunogenicity of
influenza virus in ducks (Higgins et al., 1987). In recent studies,
a reverse genetics-derived H5N1 vaccine containing the NA
gene and modified HA gene of A/goose/Guangdong/1/96
(H5N1) and the other six genes from A/PR/8/34 (H1N1) was
efficacious in chickens, geese, and ducks (Tian et al., 2005).
That study firmly established the ability of reverse genetics
derived, formalin inactivated, oil emulsion H5N1 vaccine to
reduce disease signs and viral load in domestic poultry
(including ducks and geese), with the possibility of controlling
H5N1 at the source. While this study provided useful
information, especially on vaccine efficacy in ducks and
geese, each batch of vaccine contained different amounts ofTable 1
Efficacy of inactivated H5N3 influenza vaccines in chickens
Vaccine
dose
HI titer (GMT) Tracheal shedding a
Before vaccination 21 dpv 21 dpb 3 dpc 5 dpc 7 dpc
1.2 μg <10 446 4335 0/25 0/25 0/25
0.5 μg <10 320 4101 1/25 1/25 b 0/25
0.25 μg <10 254 3171 1/25 1/25 0/25
Placebo c <10 <10 <10 1/1 Not tested—all bi
No vac <10 <10 <10 Not tested—all birds dead
dpv = days post-vaccination; dpb = days post-boost; dpc = days post challenge; GM
a Number shedding/Number tested.
b Interpreted as a false positive—no corresponding HI or EID.
c One placebo-control bird was removed from the analysis because of error in reantigen, and there was no strategy for distinguishing between
naturally infected and vaccinated birds. Additionally, as many
as three doses of vaccine containing a very large quantity
(13.8 μg) of HA were used in the goose study, and vaccine
containing 4.6 μg of HA was used in the duck study.
In the present study we tested, in both chickens and ducks,
the immunogenicity and efficacy of reverse genetics-derived
vaccine containing standardized doses of H5 hemagglutinin
derived from A/Chicken/Vietnam/C58/04 (H5N1) virus and
the N3 neuraminidase of A/Duck/Germany/1215/73 (H2N3)
virus. This vaccine was highly immunogenic and efficacious in
both ducks and chickens and may therefore be useful for
reducing the emergence of influenza viruses in both poultry
and humans.
Results
Serologic responses of chickens to standardized H5N3 vaccine
The immune response of chickens to the standardized doses
of inactivated H5N3 vaccine was determined by hemaggluti-
nation inhibition testing. Single doses of vaccine containing
0.25, 0.5, and 1.2 μg HA protein induced geometric mean HI
titers of 254, 320, and 446, respectively (Table 1). After
revaccination, these titers increased to 3171, 4101, and 4335,
respectively. The placebo and unvaccinated control groups had
no detectable HI antibody 21 days after initial vaccination, but
one of the 25 placebo-vaccinated chickens had an HI titer of
1280 after revaccination. This unlikely occurrence did not
result from introduction of live A/Chicken/Vietnam/C58/04
(H5N1) virus, or the bird would have died; the most likely
explanation is the inadvertent administration of a dose of
inactivated vaccine to this bird at the time of revaccination.
Revaccination increased the HI antibody titers by about ten-
fold, and all doses of vaccine induced high titers of HI
antibodies.
Protective efficacy of standardized H5N3 vaccine in chickens
The efficacy of the H5N3 standardized inactivated vaccine
in chickens was determined by comparing death and disease
signs in the vaccinated, placebo-vaccinated, and unvaccinatedCloacal shedding a Post-
challenge
mortality
10 dpc 14 dpc 3 dpc 5 dpc 7 dpc 10 dpc 14 dpc
0/25 0/25 0/25 0/25 0/25 0/25 0/25 0/25
0/25 0/25 0/25 0/25 0/25 0/25 0/25 0/25
0/25 0/25 0/25 0/25 0/25 0/25 0/25 0/25
rds dead 1/1 Not tested—all birds dead 24/24
Not tested—all birds dead 25/25
T = geometric mean titer.
vaccination.
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complete protection from lethal challenge: none of the 75
vaccinated birds showed any clinical sign of infection. In
contrast, all birds in the placebo group (minus the one aberrant
bird) and all of the unvaccinated birds died by the fourth day
post-challenge and showed disease signs typical of highly
pathogenic avian H5N1 influenza. The vaccine efficacy was
100% (95% CI, 86%–100%).
To measure virus shedding by vaccinated and control groups,
we obtained tracheal and cloacal swabs of all birds that were
alive starting on the third day after challenge. One of the 25
birds that received the lowest dose of H5N3 vaccine (0.25 μg
HA) had detectable tracheal virus on days 3 and 5 post-
challenge (Table 1). Virus was detected only in undiluted
samples and was not detected after day 5. One of the 25 birds
receiving the intermediate dose (0.5 μg HA) shed detectable
H5N1 virus on day 3 but not beyond, again at the lowest
detectable level. In the group receiving the largest dose of
vaccine (1.2 μg HA), none of the birds shed detectable virus.
Thus, each dose of vaccine tested was highly efficacious in
protecting chickens from infection.
Vaccination of ducks with standardized doses of inactivated
H5N3 antigen
The available evidence indicates that free-range domestic
ducks played an important role in the spread of H5N1 in
Vietnam and Thailand (Gilbert and Slingenbergh, 2004).
Backyard farms that raised both ducks and chickens were
eight times as likely to be infected with H5N1 as farms that
raised only chickens. Because no information was available
about the immune response of ducks to standardized doses of
influenza vaccine, we duplicated the chicken study in ducks.
Two experiments were conducted, the first at the same antigen
doses used in chickens (1.2, 0.5, 0.25 μg HA protein) and the
second at lower antigen doses (0.25, 0.125, 0.0625, 0.0313 μg
HA protein). Like the chickens, the ducks were vaccinated at 2
weeks of age, revaccinated at 5 weeks of age, and challenged 21
days after revaccination.
Serological and clinical effects of H5N1 vaccines in ducks
receiving standardized doses of H5N3 vaccine in ducks
Although no death and disease signs were observed in
ducks inoculated with A/Chicken/Vietnam/C58/04 (H5N1)Table 2
Efficacy of inactivated H5N3 influenza vaccine in ducks at the doses used in chicke
Vaccine
dose
Serology (HI GMT) Tracheal shedding a
21 dpv 21 dpb 25 dpc 3 dpc 5 dpc 10 dpc
1.2 μg 52 220 209 0/13 0/13 0/13
0.5 μg 45 151 142 0/12 0/12 0/12
0.25 μg 72 290 177 0/14 0/14 0/14
Placebo <10 <10 127 12/13 3/13 0/12
GMT = geometric mean titer. dpv = days post-vaccination. dpb = days post-boost. d
a Number shedding/Number tested.virus, the H5N1 virus did replicate in ducks. In the first
experiment in ducks, each of the doses of vaccine (1.2, 0.5,
0.25 μg HA) induced HI antibodies; geometric mean titers
were 52, 45, and 72, respectively, 21 days after primary
vaccination (Table 2). After revaccination, the titers rose to
220, 151, and 290, respectively. The placebo group had no
detectable antibody after primary or secondary immunization.
After oral and intratracheal inoculation with 30 50% chicken
infectious doses (CID50) of virus, all of the placebo-
vaccinated group shed virus 3 days after challenge, whereas
none of the group that received 1.2, 0.5, or 0.25 μg of HA
protein shed detectable virus. One of the placebo-control
ducks died between days 5 and 10 after challenge, while all
12 remaining ducks developed HI antibodies with titers of 40
to 320. The vaccine's efficacy in preventing virus isolation
from tracheal swabs was 100% (95% CI, 76.43%–100%),
100% (95% CI, 73.06%–100%), and 100% (95% CI,
74.86%–100%) for vaccine doses of 0.25, 0.5, and 1.2,
respectively. The vaccine's efficacy for preventing virus
isolation from cloacal swabs was 100% (95% CI, 75.07%–
100%), 100% (95% CI, 71.47%–100%), and 100% (95% CI,
73.39%–100%) for vaccine doses 0.25, 0.5, and 1.2,
respectively.
In the second experiment, in which ducks received smaller
doses of antigen (0.0313, 0.0625, and 0.125 μg HA), the HI
antibody titers were <10, 21, and 15, respectively (Table 3). The
lowest dose of vaccine (0.0313 μg HA) induced detectable HI
antibody in only 5 of 10 ducks after primary vaccination. After
vaccination with 0.0625 and 0.125 μg HA, eight of the 10
ducks in each group responded with detectable HI antibody. In
the 0.25 μg HA group, all 10 ducks produced detectable
antibody. After revaccination, all groups showed a marked
increase in HI titers, which ranged from 92 (0.0313 μg) to 435
(0.25 μg).
After challenge of the vaccinated and control ducks with 30
CID50 of A/Chicken/Vietnam/C58/04 (H5N1) virus, only the
unvaccinated control group showed replication of virus in 10/10
birds. No virus replication was detected in the ducks receiving 2
doses of 0.0313 or 0.0625 μg of HA antigen (Table 3). In
contrast, 2 of 10 ducks in the 0.125 μg antigen group and 1 of 20
in the 0.25 μg antigen group shed virus for 1 day at the lowest
detectable level. The vaccine's efficacy for prevention of
tracheal shedding was 100% (95% CI, 68.05%–100%) after 2
doses of 0.0313 to 0.0625 μg HA and 94.44% (95% CI,
73.50%–99.82%) after two doses of 0.25 μg HA, in comparisonns (first duck study)
Cloacal shedding a Post-
challenge
mortality
17 dpc 3 dpc 5 dpc 10 dpc 17 dpc
0/13 0/13 0/13 0/13 0/13 0/13
0/12 0/12 0/12 0/12 0/12 0/12
0/14 0/14 0/14 0/14 0/14 0/14
0/12 11/13 2/13 0/12 0/12 1/13
pc = days post-challenge.
Table 3
Efficacy of inactivated H5N3 influenza vaccine in ducks at lower doses of antigen (second duck study)
Vaccine
dose
Serology (HI GMT) Tracheal shedding a Cloacal shedding a Post-
challenge
mortality
21 dpv 21 dpb 21 dpc 3 dpc 5 dpc 7 dpc 11 dpc 3 dpc 5 dpc 7 dpc 11 dpc
0.25 μg b 37 435 253 1/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10
0.25 μg c 35 367 367 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10
0.125 μg 15 211 171 1/10 0/10 0/10 0/10 0/10 0/10 1/10 0/10 0/10
0.0625 μg 21 239 149 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10
0.0313 μg <10 92 121 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10
Placebo <10 <10 345 9/10 3/9 0/9 0/9 9/10 2/9 1/9 0/9 1/10
MT = geometric mean titer. dpv = days post-vaccination. dpb = days post-boost. dpc = days post-challenge.
a Number shedding/Number tested.
b Batch 1.
c Batch 2.
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shedding after two doses of 0.125 μg HAwas 88.89% (95% CI,
51.87%–99.65%) compared to control ducks commingled in
the same pens.
Re-challenge of ducks with a highly lethal H5N1 strain
Because A/Chicken/Vietnam/C58/04 is non-pathogenic in
ducks, we next tested whether this vaccine would protect
ducks from challenge with an H5N1 strain highly lethal to
ducks. We re-challenged the ducks that had been vaccinated
with 0.25 μg, 0.5 μg, and 1.2 μg of A/Chicken/Vietnam/C58/
04 (H5N1) and had been challenged once with A/chicken/
Vietnam/C58/04 (H5N1) vaccine with A/Duck/Thailand/71.1/
04 (H5N1) virus. This virus kills all ducks inoculated by the
natural route of infection within 7 days and has an intravenous
pathogenicity index (IVPI) of 2.87 in ducks (Sturm-Ramirez
et al., 2005). Thus, these ducks were challenged a second
time, first with the non lethal H5N1 strain then with the lethal
H5N1 virus. The vaccinated ducks were divided into two
groups; both groups were re-challenged with 107 EID50 of
A/Duck/Thailand/71.1/04 (H5N1) virus, one group 30 days
after the first challenge and one group 114 days after the first
challenge.Table 4
Efficacy of a single dose of inactivated H5N3 influenza vaccine in ducks after chal
Vaccine
dose
Serology (GMT) Tracheal shedding b
Pre-chall Post-chall 4 dpc 7 dpc
1.2 μg 40 20 0/8 0/8
0.5 μg 101 180 0/6 0/6
0.25 μg 40 32 0/7 0/7
0.125 μg 15 13 0/7 0/7
0.0625 μg 14 11 0/8 0/8
0.0313 μg <10 <10 0/8 0/8
0.015 μg <10 <10 0/8 0/8
Placebo <10 135 12/12 2/6
Serology values indicate HI titers; reisolation values indicate number positive/total.
a Ducks were challenged with the duck lethal A/duck/Thailand/71.1/04 (H5N1) s
b Number shedding/Number tested.
c Two ducks with severe clinical signs euthanized on day 11.None of the ducks showed disease signs and none shed
detectable virus 3 and 5 days post-challenge (results not shown).
Thus, the vaccine prepared from A/chicken/Vietnam/C58/04
(H5N1), a virus that is non-pathogenic in ducks and after
challenge with the same viruses provides complete protection
from re-challenge with a virus highly lethal to ducks. The
protection after vaccination and initial challenge lasts for at least
114 days.
Single-dose vaccination of ducks
The above studies in chickens and ducks used a prime-
and-boost regimen to ensure high antibody levels and
efficacy. In practical terms, a single dose of vaccine would
be preferable if it provided acceptable immunity. We
therefore inoculated ducks with single doses of H5N1
vaccine, then drew blood for serology and challenged them
49 days later with the lethal A/duck/Thailand/71.1/04 (H5N1)
strain. The doses of H5N3 vaccine ranged from 0.015 to
1.2 μg of HA. Prechallenge HI antibody titers ranged from
<10 (0.015 μg HA) to 101 (0.5 μg HA) (Table 4). The HI
titer of antibody to challenge virus did not increase after
challenge in the vaccinated groups of ducks (Table 4) but did
increase in the placebo-control group. This finding indicatedlenge with a duck-lethal H5N1 strain a (third duck study)
Cloacal shedding b Post-
challenge
mortality
11 dpc 4 dpc 7 dpc 11 dpc
0/8 0/8 0/8 0/8 0/8
0/6 0/6 0/6 0/6 0/6
0/7 0/7 0/7 0/7 0/7
0/7 0/7 0/7 0/7 0/7
0/8 0/8 0/8 0/8 0/8
0/8 0/8 0/8 0/8 0/8
0/8 0/8 0/8 0/8 0/8
0/6 8/12 0/6 0/6 8/12 c
train.
Table 5
Pilot study of single vs. double vaccination of khaki-Campbell ducks a
Treatment Serology (HI GMT) Tracheal shedding b Cloacal shedding b Post-
challenge
mortality
11 dpv 11 dpb 14 dpc 2 dpc 4 dpc 7 dpc 2 dpc 4 dpc 7 dpc
One vaccination 35 85 368 0/10 0/10 0/10 0/10 0/10 0/10 0/10
Two vaccinations 25 640 1280 0/10 0/10 0/10 0/10 0/10 0/9 c 0/9
Unvac. control <10 <10 1280 d 10/10 5/5 0/3 9/10 3/5 0/3 8/10
Contact control <10 <10 <10 n.d. 0/10 0/10 n.d. 0/10 0/10 0/10
a Ducks were challenged with the duck lethal A/duck/Thailand/71.1/04 (H5N1) strain.
b Number shedding/Number tested.
c One duck euthanized with no clinical signs and no virus isolation.
d Titers from two control ducks that survived challenge.
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groups.
No mortality or disease signs were detected in any of the
vaccinated ducks. In contrast, 8/12 of the placebo group died
and the remaining had severe disease signs including neuro-
logical abnormality and/or cloudy eyes. Vaccine efficacy for
prevention of mortality in pens of ducks vaccinated with the 1.2,
0.0625, 0.0313 or 0.015 μg doses of vaccine was 100% (95%
CI, 34.94%–100%). The vaccine efficacy for the prevention of
mortality in pens of ducks administered the 0.125 and 0.25 μg
doses of vaccine was 100% (95% CI, 38.63%–100%) as
compared to controls. The vaccine efficacy for the prevention of
mortality in pens of ducks administered the 0.5 μg dose of
vaccine was 100% (95% CI, 22.03%–100%) compared to
controls.
It is noteworthy that despite the absence of detectable HI
antibody in the prechallenge sera of ducks vaccinated with
0.015 μg and 0.0313 μg of HA, there was no detectable virus
replication after challenge and no disease signs or deaths,
whereas virus replication was detectable in the tracheas of 12/12
ducks that received placebo, and 8/12 died. Infectivity
neutralization tests of duck sera that showed no HI activity
failed to detect neutralization of the homologous virus (data not
shown).
Pilot vaccination study of Khaki Campbell ducks
Because many of the ducks raised in Thailand for egg
production and as backyard poultry are Khaki Campbell ducks,
a pilot study was done to determine the efficacy of inactivated
oil emulsion H5N3 vaccine in this species. A dose of vaccineTable 6




Dose (μg) Animal Hemagglutination inhibition titer
Pre-challenge Post-challeng
One 0 Duck-2 < 40
0.5 Duck-13 640 1280
Duck-67 160 160
Two 0.25 Duck-436 2560 1280
Chick-32 5120 5120
Chick-53 10,240 5120
<, less than 1:10containing 0.25 μg of HA antigen was administered to groups of
10 ducks; one group received a single dose of vaccine and the
other received a boost dose after 2 weeks. The ducks were
inoculated intratracheally and intranasally with 104 EID50 (180
DLD50) of the lethal A/duck/Thailand/71.1/04 (H5N1) strain 14
days after vaccination. After either one or two doses of vaccine,
Khaki Campbell ducks were completely protected from
challenge with the lethal A/duck/Thailand/71.1/04 (H5N1)
strain (Table 5). All of the unvaccinated control ducks showed
severe neurological symptoms and cloudy eyes, 8/10 died, and
the remaining two were severely affected. All 10 control birds
shed virus from both the trachea and cloaca by day 2. In
contrast, no virus was detected in the vaccinated birds on any
day, and the birds remained completely healthy. At day 3 after
challenge of the vaccinated birds, unvaccinated ducks were
placed in their cages to test possible virus transmission. None of
the 5 control birds showed disease signs and none shed
detectable virus or had antibody to the challenge virus. The HI
antibody titer induced by the vaccine ranged from 35 after a
single dose of vaccine to 640 after a boost dose.
Demonstration of DIVA
One of the concerns about the use of influenza vaccines in
poultry is the ability to distinguish between naturally infected
and vaccinated birds. This can be achieved by using an
irrelevant neuraminidase antigen in the vaccine—a concept
introduced by Capua et al. (2003), called “In distinguishing
infected and vaccinated animals”—DIVA. In Table 6, we
demonstrate that before challenge unvaccinated ducks had no
detectable antibodies to H5 in HI assays and background levelsantibody titer
N1 neuramindase inhibition titer N3 neuraminidase inhibition titer
e Pre-challenge Post-challenge Pre-challenge Post-challenge
< < 20 20
< < >160 >160
< < >160 >160
< < >160 >160
< < >160 >160
< < >160 >160
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the unvaccinated ducks demonstrated a small rise in level of
antibodies to H5 (1:40), but no antibodies to N1. In contrast,
birds vaccinated with H5N3 had high levels of antibodies to H5
and N3 but no detectable antibodies to N1 before or after
challenge with H5N1 virus.
Discussion
Domestic ducks and chickens appear to be the immediate
source of the H5N1 viruses that have infected humans recently
in southeast Asia, and ducks (particularly free-range ducks) are
associated with H5N1 infection in domestic chickens in
Thailand (Gilbert and Slingenbergh, 2004). After outbreaks
are initially controlled by culling infected flocks, vaccination
can help to provide continued control. Here, we have reported
the preparation and testing of a reverse genetics-derived H5N3
vaccine that induces protective immunity to highly pathogenic
H5N1 viruses in chickens and ducks. Doses of 0.25, 0.5, and
1.2 μg of A/Chicken/Vietnam/C58/04 (H5) HA protein
completely prevented disease signs in chickens, whereas the
placebo-control and unvaccinated chickens died. Only two of
50 vaccinated chickens shed virus from the cloaca at the lowest
level of detection, with infectivity titers less than 1.0 log10/ml.
The high titers of antibody induced in chickens after a single
0.25, 0.5, or 1.2 μg dose of vaccine suggest that a single
immunization with these doses of antigen would provide
protective immunity. Additional studies are planned to test this
hypothesis. The minimal dose of antigen required to provide
protective immunity was not determined in these studies, nor
whether doses below 0.25 μg HA protein are efficacious.
In ducks, either single or double doses of inactivated H5N3
oil emulsion vaccine induced protective immunity against
challenge with either less pathogenic or highly pathogenic
strains of H5N1 influenza virus. Antigen doses ranging from
0.25 to 1.2 μg of HA protein induced HI antibody titers greater
than 40; doses of 0.0625 to 0.125 μg induced detectable HI
titers of 15, while doses of 0.015 to 0.0313 μg did not induce
detectable HI antibody. However, all ducks vaccinated with the
lower antigen doses were protected from challenge with lethal
H5N1 virus. In the four different studies we conducted in ducks,
only three vaccinated birds shed virus after challenge, and then
only at the lowest detectable level.
Protection of vaccinated ducks from challenge with H5N1
virus in the absence of detectable HI antibody suggests that
either the sensitivity of the test is low or the vaccine induces
cellular immune responses. The duck sera that showed no HI
activity after vaccination failed to neutralize homologous virus
(data not shown). Thus, protection in the absence of detectable
antibody remains unexplained; it may have a cell mediated basis
or may be due to unknown properties of duck immunoglobulins
(Higgins et al., 1987).
The complete protection of ducks by a single low dose of HA
antigen (0.015 μg or more) suggests the feasibility of using
influenza vaccine in the field to control the spread of H5N1
virus in ducks. The low effective dose indicates that multiple
doses of vaccine can be produced per embryonated chicken eggand that unconcentrated allantoic fluid containing virus could be
diluted to produce multiple doses of vaccine. Tian et al. (2005)
provided the only other available information about the efficacy
of H5N1 influenza vaccines in ducks; they reported that vaccine
containing 4.6 μg of HAwas efficacious in ducks. Our findings
indicate that much lower doses of vaccine are efficacious in
ducks; this disparity may reflect differences between the
adjuvant preparations used.
Our findings provide preliminary information about the
duration of protection provided by vaccination of ducks;
rechallenge after 114 days with the highly lethal duck strain
of H5N1 induced no disease signs and no virus shedding.
However it must be kept in mind that these ducks had been
challenged once with the chicken H5N1 virus and were
therefore immunologically boosted before the rechallenge 114
days later. A single dose of vaccine may be sufficient for meat
ducks, while a booster dose may be needed to provide longer
immunity for laying ducks.
The widespread raising of free-range ducks in Vietnam and
Thailand after the rice harvest may have contributed to the
initial spread of H5N1 in 2003–2004; such ducks can be
transported by truck over relatively long distances. The rapid
evolution of the H5N1 virus in ducks between 2002 and 2005
and the emergence of variants that do not kill ducks but remain
lethal to chickens (Sturm-Ramirez et al., 2005; Hulse-Post et al.,
2005)are factors that contribute to the continuing circulation of
H5N1 viruses in southeast Asia. Not only are free-range ducks
raised, but the presence of ducks in most backyards in the
villages and towns of Asia are a continuing challenge to the
control of H5N1 influenza, especially when the circulating
strains are nonpathogenic in ducks. In 2005, Vietnam banned
the hatching of duck eggs in an attempt to reduce the risk of
H5N1 infection in poultry and humans. Our results add support
to the findings of Tian et al. (2005) that the use of oil emulsion
H5 vaccines in ducks offers an option for controlling H5N1
virus at the source.
Ducks are immunized by low doses of H5 antigen in oil
emulsion adjuvant, whereas high doses of the human counter-
part of this virus (A/Vietnam/1203/04 [H5N1]) are required to
immunize ferrets and humans. In ferrets, 7 μg of antigen
induced protective immunity (Hoffmann et al., 2005), but
adjuvants were not used.
The apparent spread of H5N1 viruses from domestic ducks
to wild migratory birds in Qinghai Lake, China (Chen et al.,
2005) raises the question whether widespread use of vaccine
contributed to or could have prevented this transfer of H5N1
virus. There is continuing controversy about the use of vaccines
in poultry and whether they contribute to or reduce antigenic
drift in this virus. Replication of H5 avian influenza virus was
demonstrated in vaccinated chickens, with the possibility of
transmission to unvaccinated birds (Swayne et al., 2001). On
the other hand, studies on poultry farms in Hong Kong
demonstrated that H5 vaccine could interrupt transmission of an
ongoing outbreak of H5N1 avian influenza (Ellis et al., 2004).
The absence of H5N1 influenza virus infection in humans and
domestic poultry in Hong Kong in 2004–2005 after adoption
of vaccination with inactivated H5 vaccine, together with
309R.G. Webster et al. / Virology 351 (2006) 303–311improved sanitation, attests to the potential for efficacious field
use of an H5 vaccine.
An important concern about poultry influenza vaccines is
the use of substandard or unstandardized vaccines. Some lots
of H5N2 vaccines from Mexico protected against disease
signs but did not prevent virus shedding and transmission to
unvaccinated birds (Garcia et al., 1998). This effect may be a
factor in the continued presence and antigenic drift of H5N2
virus in Central America (Lee et al., 2004). While veterinary
influenza vaccines with different compositions of oil emulsion
adjuvants may differ in their effectiveness, a case could be
made for considering the creation of international standards
for antigen content of veterinary influenza vaccines, as is the
case for human influenza vaccines. Veterinary vaccines
should contain, for example, no less than the minimal dose
of antigen (in terms of μg HA protein) demonstrated to have
a pre-determined standard of effectiveness. Cooperation
between companies selling vaccine internationally and
international organizations such as FAO and OIE in the
development of such standards would be likely to have sig-
nificant value.
Because the highly pathogenic H5N1 avian influenza virus is
endemic in domestic poultry in Eurasia and may be established
globally in wild migratory birds, there will be a need for high-
quality standardized vaccine. The current report describes a
reverse genetics-derived, inactivated, oil emulsion vaccine that
is effective in both chickens and ducks and can be produced
without virus concentration or purification. The possibility still
exists that the use of such a vaccine could prevent transmission
of H5N1 influenza virus to humans and prevent the emergence
of a pandemic strain. There is an urgent need for additional
regulation of veterinary influenza vaccines because of concern
that substandard and inadequately inactivated vaccines may




A/Chicken/Vietnam/C58/04 (H5N1) virus was isolated from
a moribund infected chicken and grown in chicken embryos.
This virus meets the definition of a highly pathogenic avian
influenza virus, possessing a series of basic amino acids at the
cleavage site of the HA and killing experimentally infected
chickens in less than 1 day. The intravenous pathogenicity index
(IVPI) in chickens is 3.0. A/Duck/Germany/1215/73 (H2N3)
virus was obtained from the influenza virus repository at St. Jude
Children's Research Hospital. The A/PR/8/34 (H1N1) virus
(PR8) is the strain used in the preparation of human influenza
vaccines. The highly pathogenic H5N1 viruses were handled in
BSL3+ facilities approved for studies with these viruses.
Reverse genetics
RT-PCR was performed with segment-specific primers as
previously described (Hoffmann et al., 2000). Briefly, RNAwasisolated by using the RNeasy kit (Qiagen) and transcribed to
cDNA with the Uni12-primer (AGC AAA AGC AGG).
Plasmids encoding the PB1, PB2, PA, NP, M, and NS genes
of influenza PR8 were constructed as previously described
(Hoffmann et al., 2002) and were designated pHW191-PB2,
pHW192-PB1, pHW193-PA, pHW195-NP, pHW197-M, and
pHW198-NS. The plasmid, which encoded the HA of the A/
Chicken/Vietnam/C58/04 (H5N1) virus, with a deletion of the
polybasic amino acid region at the HA1–HA2 cleavage site,
was derived by PCR amplification of two fragments.
The fragments were digested with BsmBI and inserted into
pHW2000-BsmBI by a three-fragment ligation reaction. The N3
NA of influenza A/Duck/Germany/1215/73 was cloned into the
pHW2000 vector by using PCR and the N3-specific primers
previously described (Liu et al., 2003). Hartwell Center for
Bioinformatics and Biotechnology at St. Jude Children's
Research Hospital determined DNA template sequence using
Big Dye Terminator(v.3) chemistry and synthetic oligonucleo-
tides. Samples were analyzed on Applied Biosystem 3700 DNA
Analyzers.
Generation of recombinant viruses
Recombinant viruses were generated by DNA transfection as
described by Hoffmann et al. (2002) and Liu et al. (2003).
Preparation of vaccines
Viruses were propagated in the allantoic cavities of 10- to 11-
day-old embryonated chicken eggs at 35 °C for 48 h. Allantoic
fluid was harvested, and virus was inactivated by adding 0.2%
formalin and allowing the fluid to remain at 37 °C for 24 h.
Inactivation was confirmed by the absence of detectable
infectivity after two blind passages of the treated allantoic
fluid in embryonated eggs.
The content of the hemagglutinin protein in the allantoic
fluid was standardized by the single radial immunodiffusion
technique as described previously (Wood et al., 1985), using
monospecific antiserum to the HA of A/Vietnam/1203/04
(H5N1) (Wood et al., 2001).
Vaccines were prepared from inactivated, unconcentrated
allantoic fluid of reverse genetics A/Chicken/Vietnam C58/04
(H5N1) standardized for hemagglutinin (HA) protein concen-
tration. Placebo vaccines contained virus-free allantoic fluid
from 12-day-old embryonated chicken eggs. The vaccines were
formulated in standard water in mineral oil emulsion.
Test animals
Chickens
SPF white leghorn chickens (Gallus domesticus) from
Charles River were wing-banded and provided feed and water
ad libitum. The birds were housed in pens in BSL3+ facilities;
groups of 25 birds received their first dose of vaccine at 2 weeks
of age, were revaccinated at 5 weeks of age, and were
challenged with 30 chicken lethal doses of A/Chicken/Vietnam/
C58/04 (H5N1) at 8 weeks of age. Housing in pens was such
310 R.G. Webster et al. / Virology 351 (2006) 303–311that an equal number of chickens from each treatment group
were housed in each pen.
Ducks
Outbred Pekin white ducks (Anas platyrhynchos) from Ideal
Poultry, Cameron, TX, were leg-banded and housed as
described above for the chickens with the exception that due
to constraints in availability of the BSL3+ facilities ducks could
not be arranged with an equal number from each treatment
group housed in each pen.
Animal studies
Vaccination and blood sampling
Chickens were randomly assigned to groups and vaccinated
intramuscularly in the breast. Ducks were randomly assigned to
groups and were vaccinated intramuscularly in the legs (one half
dose in each leg). Primary vaccination was given at 2 weeks of
age and revaccination at 5 weeks of age. Blood samples were
obtained from all birds before each vaccination and before
challenge. The final blood sample was obtained 74 days after
primary vaccination.
Challenge and swab sampling
Three weeks after revaccination, chickens and ducks were
challenged by intranasal instillation of 1.0 ml containing 30
CLD50 of A/Chicken/Vietnam/C58/04 (H5N1) virus. All birds
were observed daily for mortality. From day 3 through day 17
post-challenge, tracheal and cloacal swabs were collected on
designated days (2, 3, 4, 5, 7, 10, 11, 14, 17 depending on the
experiment) from all living birds for virus isolation in chicken
embryos.
In the single-vaccination duck experiment, the birds were
challenged by intranasal instillation of 1.0 ml containing 100
duck lethal doses of A/duck/Thailand/71.1/04 (H5N1) virus.
The birds were observed daily for mortality. Four, 7, and 11
days after challenge, tracheal and cloacal swabs were collected
from all living birds for virus isolation.
Serologic tests
Hemagglutination inhibition (HI) and neuraminidase inhibi-
tion (NI) tests were done as described previously (Webster et al.,
2002).
Statistical analysis
The vaccine efficacy statistics and 95% exact confidence
intervals were calculated based on the bird using the inverted
two one-sided tests methods in PROC-STATXACT (Cytel
Software Corp., Cambridge, MA).
Acknowledgments
This work was supported by Public Health Service grants
AI-95357 and CA-21765 and by the American Lebanese Syrian
Associated Charities (ALSAC). We thank Jennifer Humberd,
Ashley Baker, Yolanda Griffin, David Walker, Kelly Jones, SaraBarnes, John Franks, and Cedric Proctor for excellent technical
assistance; Carol Walsh and Amanda Ball for manuscript
preparation; and Sharon Naron for editorial assistance.
References
Brugh, M., Beard, C.W., Stone, H.D., 1979. Immunization of chickens and
turkeys against avian influenza with monovalent and polyvalent oil
emulsion vaccines. Am. J. Vet. Res. 40, 165–169.
Capua, I., Terregino, C., Cattoli, G., Mutinelli, F., Rodriguez, J.F., 2003.
Development of a DIVA (Differentiating Infected from Vaccinated Animals)
strategy using a vaccine containing a heterologous neuraminidase for the
control of avian influenza. Avian Pathol. 32, 47–55.
Chen, H., Smith, G.J., Zhang, S.Y., Qin, K., Wang, J., Li, K.S., Webster, R.G.,
Peiris, J.S.M., Guan, Y., 2005. H5N1 outbreak in migratory waterfowl.
Nature 436, 191–192.
Ellis, T.M., Leung, C.Y., Chow, M.K., Bissett, L.A., Wong, W., Guan, Y., Peiris,
J.S., 2004. Vaccination of chickens against H5N1 avian influenza in the face
of an outbreak interrupts virus transmission. Avian Pathol. 33, 405–412.
Garcia, A., Johnson, H., Srivastava, D.K., Jayawardene, D.A., Wehr, D.R.,
Webster, R.G., 1998. Efficacy of inactivated H5N2 influenza vaccines
against lethal A/Chicken/Queretaro/19/95 infection. AvianDis. 42, 248–256.
Gilbert, M., Slingenbergh, J., 2004. Highly pathogenic avian influenza in
Thailand: An analysis of the distribution on outbreaks in the 2nd wave,
identification of risk factors, and prospects for real-time monitoring. Finding
result from a joint analysis by FAO and DLD, 2–7 November 2004
Bangkok.
Higgins, D.A., Shortridge, K.F., Ng, P.L., 1987. Bile immunoglobulin of the
duck (Anas platyrhynchos): II. Antibody response in influenza A virus
infections. Immunology 62, 499–504.
Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., Webster, R.G., 2000. A
DNA transfection system for generation of influenza A virus from eight
plasmids. Proc. Natl. Acad. Sci. U.S.A. 97, 6108–6113.
Hoffmann, E., Krauss, S., Perez, D., Webby, R., Webster, R.G., 2002. Eight-
plasmid system for rapid generation of influenza virus vaccines. Vaccine 20,
3165–3170.
Hoffmann, E., Lipatov, A.S., Webby, R.J., Govorkova, E.A., Webster, R.G.,
2005. Role of specific hemagglutinin amino acids in the immunogenicity
and protection of H5N1 influenza virus vaccines. Proc. Natl. Acad. Sci.
U.S.A. 102, 12915–12920.
Horimoto, T., Kawaoka, Y., 2005. Influenza: lessons from past pandemics,
warnings from current incidents. Nat. Rev., Microbiol. 3, 591–600.
Hulse-Post, D.J., Sturm-Ramirez, K.M., Humberd, J., Seiler, P., Govorkova,
E.A., Krauss, S., Scholtissek, C., Puthavathana, P., Buranathai, C.,
Nguyen, T.D., Long, H.T., Naipospos, T.S., Chen, H., Ellis, T.M., Guan,
Y., Peris, J.S., Webster, R.G., 2005. Role of domestic ducks in the
propagation and biological evolution of highly pathogenic H5N1 influenza
viruses in Asia. Proc. Natl. Acad. Sci. U.S.A. 102, 10682–10687.
Karunakaran, D., Newman, J.A., Halvorson, D.A., Abraham, A., 1987.
Evaluation of inactivated influenza vaccines in market turkeys. Avian Dis.
31, 498–503.
Lee, C.W., Senne, D.A., Suarez, D.L., 2004. Effect of vaccine use in the
evolution of Mexican lineage H5N2 avian influenza virus. J. Virol. 78,
8372–8381.
Lee, C.W., Swayne, D.E., Linares, J.A., Senne, D.A., Suarez, D.L., 2005. H5N2
avian influenza outbreak in Texas in 2004: the first highly pathogenic strain
in the United States in 20 years. J. Virol. 19, 11412–11421.
Lipatov, A.S., Govorkova, E.L., Webby, R.J., Ozaki, H., Peiris, M., Guan, Y.,
Poon, L., Webster, R.G., 2004. Influenza: emergence and control. J. Virol.
78, 8951–8959.
Liu, M., Wood, J.M., Ellis, T., Krauss, S., Seiler, P., Johnson, C., Hoffmann, E.,
Humberd, J., Hulse, D., Zhang, Y., Webster, R.G., Perez, D.R., 2003.
Preparation of a standardized, efficacious agricultural H5N3 vaccine by
reverse genetics. Virology 314, 580–590.
Liu, J., Xiao, H., Lei, F., Zhu, Q., Qin, K., Zhang, X.W., 2005. Highly
pathogenic H5N1 influenza virus infection in migratory birds. Science 309,
1206.
311R.G. Webster et al. / Virology 351 (2006) 303–311Qiao, C.L., Yu, K.Z., Jiang, Y.P., Jia, Y.Q., Tian, G.B., Liu, M., Deng, G.H.,
Wang, X.R., Meng, Q.W., Tang, X.Y., 2003. Protection of chickens against
highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant
fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase
genes. Avian Pathol. 32, 25–32.
Sims, L.D., Guan, Y., Ellis, T.M., Liu, K.K., Dyrting, K., Wong, H., Kung, N.Y.,
Shortridge, K.F., Peiris, M., 2003. An update on avian influenza in Hong
Kong 2002. Avian Dis. 47, 1083–1086.
Stone, H.D., 1987. Efficacy of avian influenza oil-emulsion vaccines in chickens
of various ages. Avian Dis. 31, 483–490.
Sturm-Ramirez, K.M., Hulse-Post, D.J., Govorkova, E.A., Humberd, J., Seiler,
P., Puthavathana, P., Buranathai, C., Nguyen, T.D., Chaisingh, A., Long,
H.T., Naipospos, T.S., Chen, H., Ellis, T.M., Guan, Y., Peris, J.S., Webster,
R.G., 2005. Are ducks contributing to the endemicity of highly pathogenic
H5N1 influenza virus in Asia? J. Virol. 79, 11269–11279.
Swayne, D.E., Beck, J.R., Mickle, T.R., 1997. Efficacy of recombinant fowl
poxvirus vaccine in protecting chickens against a highly pathogenic
Mexican-origin H5N2 avian influenza virus. Avian Dis. 41, 910–922.
Swayne, D.E., Garcia, M., Beck, J.R., Kinney, N., Suarez, D.L., 2000.
Protection against diverse highly pathogenic H5 avian influenza viruses in
chickens immunized with a recombinant fowlpox vaccine containing an H5
avian influenza hemagglutinin gene insert. Vaccine 18, 1088–1095.Swayne, D.E., Beck, J.R., Perdue, M.L., Beard, C.W., 2001. Efficacy of
vaccines in chickens against highly pathogenic Hong Kong H5N1 avian
influenza. Avian Dis. 45, 355–365.
Tian, G., Zhang, S., Li, Y., Bu, Z., Liu, P., Zhou, J., Li, C., Shi, J., Yu, K., Chen,
H., 2005. Protective efficacy in chickens, geese and ducks of an H5N1-
inactivated vaccine developed by reverse genetics. Virology 341, 153–162.
Webster, R.G., Guan, Y., Peiris, M., Walker, D., Krauss, S., Zhou, N.N.,
Govorkova, E.A., Ellis, T.M., Dyrting, K.C., Sit, T., Perez, D.R., Shortridge,
K.F., 2002. Characterization of H5N1 influenza viruses that continue to
circulate in geese in southeastern China. J. Virol. 76, 118–126.
Wood, J.M., Kawaoka, Y., Newberry, L.A., Bordwell, E., Webster, R.G., 1985.
Standardization of inactivated H5N2 influenza vaccine and efficacy against
lethal A/Chicken/Pennsylvania/1370/83 infection. Avian Dis. 29, 867–872.
Wood, J.M., Nicholson, K.G., Zambon, M., Hinton, R., Major, D.L., Newman,
R.W., Dunleavy, U., Melzack, D., Robertson, J.S., Schild, G.C., 2001.
Developing vaccines against potential pandemic influenza viruses. In:
Osterhaus, A.D.M.E., Cox, N., Hmpson, A.W. (Eds.), Options for the
Control of Influenza IV. Excerpta Medica, Amsterdam, pp. 751–759.
Xu, X.Y., Subbarao, K., Cox, N.J., Guo, Y.J., 1999. Genetic characterization of
the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity
of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks
in Hong Kong. Virology 261, 15–19.
